65,437 trials
Acute Myeloid Leukemia · Lymphoblastic Leukemia · Acute Leukemia
Primary: Number of Participants With Grade 4 TMI Toxicity — 0; 0; 0; 2 Participants
Sleep Deprivation · Insufficient Sleep Syndrome · Healthy
Primary: The Effects of the Auditory Stimulation on the Cumulative or Average Slow-wave Activity (SWA) Delivered by the PowerSleep & Northwestern Systems in Adults With Mildly…
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 — 38.7; 50.8; 45.0 percentage of participants — p== 0.166
Short Bowel Syndrome
Primary: Number of Participants With Adverse Events (AEs) in Retrospective Observation Period — 23; 4; 23; 4 Participants
Jaw, Edentulous
Primary: Comparison of Distance Between First Bone to Implant Contact Point (fBIC) and Microgap (MG), After 25 Years of Function, Between All B, All SW, and All SC Dental Implant…
Unresectable Stage IIIB-IV Malignant Melanoma
Primary: Number of Participants Who Experienced One or More Dose Limiting Toxicities (DLTs) — 0 Participants
Healthy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events — 2; 3; 0; 0 Participants
Coccygodynia
Primary: Pain Change From Baseline at 2 Years — 59.08; 19.35; 20.28 units on a scale
Prostate Cancer · Prostate Adenocarcinoma · Prostate Cancer Recurrent
Primary: Correct Localization Rate (CLR) — 85.6; 87.0; 84.8 percentage of participants
Myeloid Leukemia, Chronic, Chronic Phase
Primary: Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at…
Peripheral Artery Disease
Primary: Visualization of Vessel Morphology: Layered Structure — 1.61; 1.49 score on a scale
Arthroplasty, Replacement, Knee
Primary: Survival Rate — 2; 1; 1; 4 Participants
Adenocarcinoma, Gastric · Neoplasm, Breast
Primary: Treatment-emergent Adverse Events Following Treatment With DS-8201a (Trastuzumab Deruxtecan) — 12; 12; 7; 6 Participants
NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease
Primary: Percent Change in Liver Fat Between Baseline and 12 Weeks Post-surgery — -16.4 percent change
Cerebrovascular Stroke · Upper Extremity Paresis
Primary: Fugl-Meyer Assessment, Upper Limb (FMA-UE) Average Change — 5.0; 2.4 units on a scale — p=0.0014